Neurologia Medico-Chirurgica 2012-01-01

Neuromyelitis optica spectrum disorder: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography findings--case report.

Hirofumi Oyama, Shigeru Miwa, Tomoyuki Noda, Atsuhiro Sobajima, Akira Kito, Hideki Maki, Kenichi Hattori, Kentaro Wada

Index: Neurol. Med. Chir. (Tokyo) 52(10) , 769-73, (2012)

Full Text: HTML

Abstract

A 51-year-old female with a history of rheumatoid arthritis rapidly developed anterior neck pain and paresis in the left upper and lower extremities and right lower extremity, sensory disturbance in the left upper and lower extremities, and bladder and rectal disorder. Adduction of the left eye and abduction of the right eye were also disturbed. Spinal magnetic resonance imaging demonstrated severe edema in the C1-T5 levels, which then deteriorated rapidly over 3 days, and lesions enhanced with gadolinium in the C1-C3 and C5-T3 levels. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography study demonstrated the inflammatory sites as segmental enhanced accumulation in the C1-C3, C5-C6, and T1 levels. The serum anti-aquaporin 4 antibody level was positive and she was diagnosed with neuromyelitis optica spectrum disorder. Marked improvement in the neurological conditions, concomitant with reduced spinal cord edema, was obtained by steroid pulse therapy.


Related Compounds

  • Methylprednisolone...

Related Articles:

Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.

2013-09-01

[Cancer Chemother. Pharmacol. 72(3) , 509-13, (2013)]

A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.

2012-01-01

[BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)]

Shoe contact dermatitis: a case report of an acute severe reaction to potassium dichromate.

2012-09-01

[Foot (Edinb.) 22(3) , 141-5, (2012)]

Ex vivomodels to evaluate the role of ocular melanin in trans-scleral drug delivery

2012-08-15

[Eur. J. Pharm. Sci. 46(5) , 475-83, (2012)]

Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.

2013-08-01

[JAMA Neurol. 70(8) , 1056-9, (2013)]

More Articles...